GlassScriptPhysician profile
Wayne J Reynolds
NPI 1851366173
$9,479.15
in general payments reported to CMS, 2019-2025
21 companies · $792 in 2025
The $792 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,672 · 2020: $1,066 · 2021: $2,004 · 2022: $1,480 · 2023: $1,414 · 2024: $1,051 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,291.64 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Janssen Pharmaceuticals, INC | $1,626.84 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $1,124.89 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $891.57 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Biohaven Pharmaceuticals, INC. | $688.11 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $443.65 | 2019-2022 | |
| Glaxosmithkline, LLC. | $430.63 | 2020-2024 | Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $367.30 | 2022 | |
| Scpharmaceuticals INC. | $266.51 | 2024-2025 | |
| Pfizer INC. | $260.05 | 2019-2025 | |
| Abbvie INC. | $247.21 | 2022-2023 | |
| Amarin Pharma, INC. | $131.95 | 2019-2021 | |
| Corium, LLC | $125.01 | 2023 | Azstarys |
| Astellas Pharma US INC | $125.00 | 2023 | Veozah |
| Vertex Pharmaceuticals Incorporated | $110.00 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $108.13 | 2025 | General - Pain Management |
| Alkermes, INC. | $100.33 | 2025 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $87.63 | 2025 | Caplyta |
| Mylan Specialty L.P. | $39.27 | 2023 | Yupelri |
| Phathom Pharmaceuticals, INC. | $13.43 | 2024 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Reynolds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.